Targeting novel signaling pathways for resistant acute myeloid leukemia

Kathleen M. Sakamoto*, Steven Grant, Diana Saleiro, John D. Crispino, Nobuko Hijiya, Francis Giles, Leonidas Platanias, Elizabeth A. Eklund

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

52 Scopus citations


Acute myeloid leukemia (AML) is a hematologic malignancy that is the most common type of acute leukemia diagnosed in adults and the second most common type in children. The overall survival is poor and treatment is associated with significant complications and even death. In addition, a significant number of patients will not respond to therapy or relapse. In this review, several new signaling proteins aberrantly regulated in AML are described, including CREB, Triad1, Bcl-2 family members, Stat3, and mTOR/MEK. Identifying more effective and less toxic agents will provide novel approaches to treat AML.

Original languageEnglish (US)
Pages (from-to)397-402
Number of pages6
JournalMolecular Genetics and Metabolism
Issue number3
StatePublished - Mar 1 2015


  • Acute myeloid leukemia
  • Novel therapies
  • Resistance
  • Signaling pathways

ASJC Scopus subject areas

  • Genetics
  • Endocrinology
  • Molecular Biology
  • Biochemistry
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Targeting novel signaling pathways for resistant acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this